Hayashi Hidetoshi

ハヤシヒデトシ | Hayashi Hidetoshi

Affiliation and department：

Research field (1)： Tumor diagnostics and therapeutics

Research keywords (3)： Gene analysis , medical oncology , immune checkpoint inhibitor

Research theme for competitive and other funds (3)：

2019 - 2022 Immune related gene-expression profiling for the combination of chemotherapy and PD-1/PD-L1 inhibition.
2016 - 2018 Resistance mechanis of molecular targeted therapy and tumor micro environment as the immune-checkpoint inhibitor's biomarker
2014 - 2017 未治療原発不明癌に対する次世代シークエンスを用いた原発巣推定に基づく治療効果の意義を問う第 II 相試験

Papers (137)：

Hidetoshi Hayashi, Kazuhiko Nakagawa. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. International Journal of Clinical Oncology. 2020. 25. 5. 818-830
Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, Shigeki Shimizu, Shuta Tomida, Takashi Niwa, Toshihide Yokoyama, Yasushi Fukuda, Yasutaka Chiba, Ryoji Kato, et al. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer. Clinical Cancer Research. 2020
Yoshimasa Shiraishi, Junji Kishimoto, Kentaro Tanaka, Shunichi Sugawara, Haruko Daga, Katsuya Hirano, Koichi Azuma, Osamu Hataji, Hidetoshi Hayashi, Motoko Tachihara, et al. Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clinical lung cancer. 2020
Nobuyuki Yamamoto, Hidetoshi Hayashi, David Planchard, Teresa Morán, Vanesa Gregorc, Jonathan Dowell, Hiroshi Sakai, Kiyotaka Yoh, Makoto Nishio, Alexis B Cortot, et al. A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer. Investigational new drugs. 2020
Takashi Seto, Koichi Azuma, Takeharu Yamanaka, Shunichi Sugawara, Hiroshige Yoshioka, Kazushige Wakuda, Shinji Atagi, Yasuo Iwamoto, Hidetoshi Hayashi, Isamu Okamoto, et al. Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020. 38. 8. 793-803

ｍore...

MISC (161)：

ｍore...

Lectures and oral presentations (4)：

Prognostic impact of EMT-related genes on post-operative prognosis in hepatocellular carcinoma.
(AACR 103rd Annual Meeting 2011 2012)
進行肺腺癌を対象としたゲフィチニブ/S-1併用療法第1層臨床試験
(第51回日本肺癌学会総会 2010)
進行肺腺癌を対象としたゲフェチニブ/S-1 併用療法第1相臨床試験
(第92回日本肺癌学会関西支部会 2010)
ソラフェニブは肺癌細胞においてKRAS野生型に対しては
(第8回日本臨床腫瘍学会総会 2010)

Education (2)：

1997 - 2003 Osaka University Medical School
Kindai University

Professional career (1)：

医学博士 (近畿大学)

Work history (7)：

2020/04 - 現在近畿大学医学部内科学腫瘍内科講師
2015/10 - 現在 Kindai university hospital Department of Medical Oncology Lecturer
2015/04 - 2015/09 Kindai university hospital Department of Medical Oncology Assistant professor
2013/04 - 2015/03 Kishiwada City Hospital Department of Medical Oncology Director
2009/04 - 2013/03 Kindai university hospital Department of Medical Oncology assistant professor

Show all

Committee career (5)：

2020/02 - 現在 International Association for the Study of Lung Cancer Membership committee
2017 - 現在日本臨床腫瘍学会学術集会部会委員
2017 - 現在日本がん治療認定医機構教育委員会専門部会委員
2014 - 現在日本臨床腫瘍学会頭頚部がんガイダンス作成協力委員
2019/06 - 日本臨床腫瘍学会専門医審査部会

Awards (2)：

2015/07 - 日本臨床腫瘍学会日本臨床腫瘍学会奨励賞
2008/06 - 西日本がん研究機構西日本がん研究機構賞

Association Membership(s) (5)：

American Society of Clinical Oncology , 日本臨床腫瘍学会 , THE JAPAN LUNG CANCER SOCIETY , THE JAPANESE SOCIETY OF INTERNAL MEDICINE , International Association for the Study of Lung Cancer

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page